PubRank

Cyclooxygenase-2 (COX-2) Inhibitor Reduces Serum Prostatic Specific Antigen (PSA) Levels

Clinical Trial ID NCT01678313

PubWeight™ 0.92‹?›

🔗 Visit the ClinicalTrials.gov page for NCT01678313

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Safety and morbidity of first and repeat transrectal ultrasound guided prostate needle biopsies: results of a prospective European prostate cancer detection study. J Urol 2001 2.83
2 Is there evidence of a relationship between benign prostatic hyperplasia and prostate cancer? Findings of a literature review. Eur Urol 2008 2.65
3 Distribution of inflammation, pre-malignant lesions, incidental carcinoma in histologically confirmed benign prostatic hyperplasia: a retrospective analysis. Eur Urol 2003 2.17
4 Associations between C-reactive protein and benign prostatic hyperplasia/lower urinary tract symptom outcomes in a population-based cohort. Am J Epidemiol 2009 1.92
5 Inflammation and chronic prostatic diseases: evidence for a link? Eur Urol 2007 1.61
6 Prostate growth and inflammation. J Steroid Biochem Mol Biol 2007 1.33
7 Combination therapy with rofecoxib and finasteride in the treatment of men with lower urinary tract symptoms (LUTS) and benign prostatic hyperplasia (BPH). Eur Urol 2005 1.27
8 Urinary nerve growth factor levels are increased in patients with bladder outlet obstruction with overactive bladder symptoms and reduced after successful medical treatment. Urology 2008 1.14
9 LUTS treatment: future treatment options. Neurourol Urodyn 2007 1.13
10 Celecoxib for treatment of nocturia caused by benign prostatic hyperplasia: a prospective, randomized, double-blind, placebo-controlled study. Urology 2008 1.10
11 Bone marrow fat: linking adipocyte-induced inflammation with skeletal metastases. Cancer Metastasis Rev 2014 0.92
12 Videourodynamic analysis of pathophysiology of men with both storage and voiding lower urinary tract symptoms. Urology 2007 0.92
13 Effects of intravesical instillation of cyclooxygenase-2 inhibitor on the expression of inducible nitric oxide synthase and nerve growth factor in cyclophosphamide-induced overactive bladder. BJU Int 2006 0.87
14 Combination therapy with doxazosin and tenoxicam for the management of lower urinary tract symptoms. Urology 2009 0.85
Next 100